Shanghai Cell Therapy wins first China trial nod for non-viral vector CAR-T therapy

China-based Shanghai Cell Therapy Group Co., Ltd's BZ019, a non-viral vector cluster of differentiation 19 (CD19) chimeric antigen receptor T-cell (CAR-T) therapy, reportedly gained clinical trial approval from the National Medical Products Administration (NMPA). The indication is CD19-positive relapsed or refractory diffuse large B-cell lymphoma. The approval is hailed as a first for domestic CAR-T cell products in terms of a non-viral vector-based therapy entering into th clinical setting.

BZ019 makes use of a non-viral vector for transfections, in contrast with previous CAR-T cell therapeutics that have entered the clinic in China. CAR-T cells prepared using non-viral vectors have the potential to benefit from several advantages, including low toxicity and immunogenicity, lower cost of production, and good reproducibility, according to the company.


Recent news
A Sino-US team of researchers have reported developing a new improved chimeric antigen receptor (CAR) T cell therapy, according to a study published in Nature Medicine.
  • 1556168634038
  • China
  • R&D
China-based Viva Biotech Holdings (1873.HK) announced an initial public offering (IPO) of 345,000,000 shares with price ranging from HKD 3.42 to HKD 4.41 per share.
Switzerland-based ADC Therapeutics and the China-based Adagene announced a discovery partnership and licensing deal focused on the development of next-generation masked antibody drug conjugates (ADCs).
U.S.-based Boston Children's Hospital (BCH) and Sino-US high-end clinics operator and healthcare service provider MORE Health Inc., announced a strategic partnership that will allow Chinese patients to access BCH's physicians for diagnosis and treatment.
China’s National Medical Products Administration (NMPA) released the medical devices awarded market approval during March 2019.
The Brazilian Society of Diabetes (SBD) this week will discuss the benefits of Technosphere insulin, a fast-acting inhalable diabetes treatment.
Brazil's Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) this month presented the results of a study on the viability of the drug inverse logistics system, commissioned to Netherlands-based consulting firm KPMG.
Analytics Snapshot

Actionable intelligence at your fingertips.